|Mr. David J. Arthur||CEO, Pres & Director||275.15k||N/A||1963|
|Mr. Mark J. Rosenblum||Exec. VP of Fin. & Interim CFO||N/A||N/A||1953|
|Mr. Sunil Sharma M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Mr. Scott Jordan||Chief Bus. Officer||N/A||N/A||1967|
Salarius Pharmaceuticals, Inc. a clinical-stage oncology company, develops therapies for the treatment of patients with various cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. It has a collaborative partnership with The Ivy Brain Tumor Center at the Barrow Neurological Institute to to develop cancer treatment for glioblastoma. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Salarius Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.